Page 237 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
Haematologica | 110 January 2025
229
Table 1. Comparison of baseline characteristics and outcomes of patients treated with multiple myeloma regimens as part of standard of care in the real world ver- sus and in the corresponding randomized clinical trial.
Baseline characteristics
TIE-NDMM RRMM
VRd Rd Kd KRd DVd DRd Pd
Median age in years at treatment initiation (IQR or range)
75 63 79 73 68 65 68 64 70 64 72 65 70 64 (IQR, 73-79) (IQR, 56-70) (IQR, 74-84) (range, 44-91) (IQR, 61-74) (IQR, 58-72) (IQR, 59-73) (range, 38-87) (IQR, 63-76) (range, 30-88) (IQR, 65-77) (range, 34-89) (IQR, 62-77) (range, 34-84)
Male sex, N (%)
160 (57)
153 (63)
452 (55)
294 (55)
287 (58)
240 (52)
177 (62)
215 (54)
355 (57)
NR 454 (58)
NR 365 (56)
181 (60)
CCI,c N (%) ≥2
116 (41) 166 (59)
NR NR
335 (41) 489 (59)
NR NR
425 (85) 73 (15)
NR NR
246 (86) 41 (14)
NR NR
507 (81) 120 (19)
NR 564 (72) NR 221 (28)
NR 521 (80) NR 127 (20)
NR NR
<2
Median months between diagnosis and treatment initiation (IQR or range)
1 (IQR, 1-5)
2 (IQR, 1-12)
45 (IQR, 27-70)
25
(IQR, 15-48) (range, 5-236) (IQR, 27-68) (range, 8-248) (IQR, 20-59) (range, 5-324) (IQR, 28-72) (range, 7-360)
Prior exposure at treatment initiation, N (%)
102 (36) 0
0 1-5* 33 (12) 0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
464 (93) 1-5* 158 (32) 58 (12) 468 (94) 31 (6)
177 (38) 211 (45) NR NR 250 (54) 2 (<1)
187 (65) 1-5* 21-25* 15-19* 264 (92) 8 (3)
79 (20) NRb NRb NR 261 (66) NR
597 (95) 0
49 (8) 60 (10) 504 (80) 48 (8)
89 (36) 125 (50) NR NR 162 (65) NR
515 (66) 1-5* 1-5* 76 (10) 749 (95) 62 (8)
50 (18) 122 (43) 2 (<1) 2 (<1) 241 (84) 6 (2)
585 (90) 1-5* 33 (5) 70 (11) 582 (90) 124 (19)
302 (100) 173 (57) 0
NR 302 (100) NR
Lenalidomide
Thalidomide
Pomalidomide
Ixazomib
Bortezomib
Carfilzomib
Isatuximab 0 Daratumumab 0 Transplant
6-10* NR 0 NR 0 NR 0 0 1-5* NR 188 (38) NR 6 (2) NR 20 (3) NR 15 (2) 0 115 (18) NR 320 (64) NR 142 (49) 217 (55) 387 (62) 157 (63) 345 (44) 180 (63) 333 (51) 214 (71)
RW SWOG RW FIRST RW ENDEAVOUR RW ASPIRE RW CASTOR RW POLLUX RW MM-003
N=282 S0777 N=824 N=535a N=498 N=464 N=287 N=396 N=627 N=251 N=785 N=286 N=648 N=302 N=242
NR
NR
NR
36
43
46 35
42 47
64
aContinuous Rd arm. bASPIRE trial reported that 39% (N=154) of the KRd group had prior exposure to pomalidomide or thalidomide. cCalculated using the Deyo-modified CCI. CCI: Charl- son comorbidity Index; MM: multiple myeloma; TIE-NDMM: newly diagnosed transplant-ineligible MM; RRMM: relapsed refractory MM; RW: real world; RCT: randomized control trial; NR: not reported; IQR: interquartile range; Rd: lenalidomide and dexamethasone; VRd: bortezomib and Rd; Kd: carfilzomib and dexamethasone; KRd: carfilzomib and Rd; DVd: daratumum- ab and bortezomib; DRd: daratumumab and Rd; Pd: pomalidomide and dexamethasone; mPFS: median progression-free survival; mOS: median overall survival. *Given confidentiality regulations with IC/ES data, subgroups representing <5% of the population cannot be enumerated, and therefore an estimate range of the number of patients is provided.